$20.610
-0.148 (-0.72%)At close
SPTX Comparative Benchmarking
In the context of the broader market, SPTX competes directly with industry leaders such as NBTX and MNKD. With a market capitalization of $1.11B, it holds a significant position in the sector. When comparing efficiency, SPTX's gross margin of N/A stands against NBTX's 100.00% and MNKD's 69.00%. Such benchmarking helps identify whether Seaport Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Seaport Therapeutics Inc Financial Performance
Seaport Therapeutics has shown a significant improvement in its current ratio, rising to 18.00 in Q2 2026 from 0.00 in previous quarters, indicating strong liquidity. However, it reported a net income loss of -62.6 million USD in Q2 2026, which raises concerns about profitability.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.